Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.55 |
| ▸ | TDO2 | P48775 | 3/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | DPP4 | P27487 | 2/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17842003 | 0.87 | IDO1 (0.43) | IDO1TDO2GAACES2CES1 | |
| SCHEMBL17842404 | 0.85 | IDO1 (0.47) | IDO1TDO2GAAOPRM1OPRD1 | |
| SCHEMBL17842282 | 0.84 | ADRB2 (0.42) | IDO1TDO2GAA | |
| SCHEMBL9729013 | 0.84 | HTR2A (0.41) | IDO1TDO2GAADPP4CES2 | |
| SCHEMBL694825 | 0.84 | IDO1 (0.41) | IDO1TDO2GAACES2CES1 | |
| SCHEMBL9719141 | 0.83 | DPP4 (0.55) | DPP4F2 | |
| Hydrochloric Acid SCHEMBL32690499 | 0.82 | IDO1 (0.43) | IDO1TDO2GAA | |
| SCHEMBL693956 | 0.79 | IDO1 (0.41) | IDO1TDO2GAADPP4F2 | |
| SCHEMBL10559802 | 0.79 | CFTR (0.47) | IDO1TDO2GAA | |
| SCHEMBL12789396 | 0.77 | DPP4 (0.44) | IDO1TDO2GAADPP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2771332-B1 | Thiophen and thiazol sulfonamid derivatives as HIV protease inhibitors for the treatment of AIDS | MERCK CANADA INC (CA) | 2016-06-29 | — | — | EP | disclosed |
| EP-2066620-A1 | DI-AROMATIC SUBSTITUTED AMIDES AS INHIBITORS FOR GLYT1 | F. Hoffmann-Roche AG (CH) | 2009-06-10 | — | — | EP | disclosed |
| US-20080076806-A1 | Di-aromatic substituted amides as inhibitors for GlyT-1 | F. HOFFMANN-LA ROCHE AG (CH) | 2008-03-27 | — | — | US | disclosed |
| WO-2008022938-A1 | DI-AROMATIC SUBSTITUTED AMIDES AS INHIBITORS FOR GLYT1 | F. HOFFMANN-LA ROCHE AG (CH) | 2008-02-28 | — | — | WO | disclosed |
| US-4865764-A | 5-aryl-11-substituted-5H,11H-pyrrolo[2,1-][1,4]benzoxazepines as hypotensive agents | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1989-09-12 | — | — | US | disclosed |
| EP-0300356-A1 | 5-Aryl-11-substituted-5H, 11H-pyrrolo[2,1-c][1,4]benzoxazepines, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1989-01-25 | — | — | EP | disclosed |
| US-4794110-A | ENANTIOMORPHS | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1988-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076806-A1 | Di-aromatic substituted amides as inhibitors for GlyT-1 | AGXT, SLC1A2, GRIA1 | IDO1 290/4885TDO2 809/4885GAA 497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.